EA
ADMS

Emerald Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

Emerald Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-642,226
Closed -$2.65M – 363
2020
Q3 		$2.65M Sell
642,226
-26,816
-4% -$104K 0.11% 122
2020
Q2 		$1.71M Buy
669,042
+37,595
+6% +$110K 0.07% 128
2020
Q1 		$1.82M Buy
631,447
+2,323
+0.4% +$10.4K 0.11% 117
2019
Q4 		$2.38M Sell
629,124
-9,970
-2% -$47.7K 0.1% 121
2019
Q3 		$3.27M Sell
639,094
-61,082
-9% -$377K 0.15% 114
2019
Q2 		$4.34M Buy
700,176
+73,929
+12% +$425K 0.17% 113
2019
Q1 		$4.45M Sell
626,247
-24,102
-4% -$217K 0.18% 116
2018
Q4 		$5.55M Sell
650,349
-12,195
-2% -$159K 0.27% 105
2018
Q3 		$13.3M Buy
662,544
+22,610
+4% +$531K 0.49% 93
2018
Q2 		$16.5M Buy
639,934
+13,821
+2% +$383K 0.62% 78
2018
Q1 		$15M Buy
626,113
+83,216
+15% +$2.62M 0.6% 71
2017
Q4 		$18.4M Buy
542,897
+14,830
+3% +$414K 0.71% 56
2017
Q3 		$11.2M Sell
528,067
-4,660
-0.9% -$85.4K 0.45% 87
2017
Q2 		$9.32M Buy
532,727
+14,042
+3% +$232K 0.39% 96
2017
Q1 		$9.08M Buy
518,685
+140
+0% +$2.39K 0.37% 99
2016
Q4 		$8.76M Buy
518,545
+14,071
+3% +$218K 0.37% 98
2016
Q3 		$8.28M Sell
504,474
-5,720
-1% -$86.9K 0.37% 101
2016
Q2 		$7.72M Hold
510,194
– – 0.37% 97
2016
Q1 		$7.38M Buy
510,194
+48,143
+10% +$811K 0.36% 97
2015
Q4 		$13.1M Buy
462,051
+110,530
+31% +$1.86M 0.62% 60
2015
Q3 		$5.88M Buy
351,521
+2,800
+0.8% +$63.7K 0.31% 111
2015
Q2 		$9.14M Buy
348,721
+26,090
+8% +$507K 0.44% 77
2015
Q1 		$5.65M Buy
322,631
+82,464
+34% +$1.41M 0.28% 118
2014
Q4 		$4.17M Buy
240,167
+79,704
+50% +$1.21M 0.22% 135
2014
Q3 		$2.99M Buy
160,463
+8,844
+6% +$152K 0.18% 164
2014
Q2 		$2.77M Buy
+151,619
New +$2.72M 0.16% 174

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Emerald Advisers's ADMS Position: Q4 2020 in Review

Emerald Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q4 2020, closing a stake of 642,226 shares — an estimated $2.65M sold.

Emerald Advisers first reported a position in ADMS in Q2 2014 and held it in 26 quarters. The position peaked at $18.4M in Q4 2017. 65 funds tracked by Wall St. Rank hold ADMS as of Q4 2020.

  • Emerald Advisers reported no remaining Adamas Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Emerald Advisers sold 642,226 Adamas Pharmaceuticals shares in Q4 2020, an estimated $2.65M.
  • Emerald Advisers first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 26 quarters.
  • Emerald Advisers's Adamas Pharmaceuticals position peaked at $18.4M in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2020.

Based on Emerald Advisers's 13F filing for Q4 2020, filed 29 Jan 2021.